Are vitiligo treatments cost-effective? A systematic review

E. McManus; T. Sach; N. J. Levell

doi:10.1111/bjd.15881

Are vitiligo treatments cost-effective? A systematic review

E. McManus, T. Sach, N. J. Levell

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

15 Downloads (Pure)

Abstract

Vitiligo is characterised by well demarcated, cutaneous, macular depigmentation, with worldwide prevalence estimated to be between 0.2-1.8% [1]. Vitiligo treatments aim to encourage re-pigmentation and include topical corticosteroids, calcineurin inhibitors and NB-UVB phototherapy. Camouflage can also be prescribed to help mask the appearance of vitiligo, although this is frequently only prescribed for the face.

Original language	English
Pages (from-to)	e57–e58
Journal	British Journal of Dermatology
Volume	178
Issue number	1
Early online date	29 Dec 2017
DOIs	https://doi.org/10.1111/bjd.15881
Publication status	Published - Jan 2018

Access to Document

10.1111/bjd.15881

Accepted manuscriptAccepted author manuscript, 404 KB

http://doi.wiley.com/10.1111/bjd.15881

Cite this

@article{f510e4e9e3f04f01989d9d7aa5554e3f,

title = "Are vitiligo treatments cost-effective? A systematic review",

abstract = "Vitiligo is characterised by well demarcated, cutaneous, macular depigmentation, with worldwide prevalence estimated to be between 0.2-1.8% [1]. Vitiligo treatments aim to encourage re-pigmentation and include topical corticosteroids, calcineurin inhibitors and NB-UVB phototherapy. Camouflage can also be prescribed to help mask the appearance of vitiligo, although this is frequently only prescribed for the face.",

author = "E. McManus and T. Sach and Levell, {N. J.}",

year = "2018",

month = jan,

doi = "10.1111/bjd.15881",

language = "English",

volume = "178",

pages = "e57–e58",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Are vitiligo treatments cost-effective? A systematic review

AU - McManus, E.

AU - Sach, T.

AU - Levell, N. J.

PY - 2018/1

Y1 - 2018/1

N2 - Vitiligo is characterised by well demarcated, cutaneous, macular depigmentation, with worldwide prevalence estimated to be between 0.2-1.8% [1]. Vitiligo treatments aim to encourage re-pigmentation and include topical corticosteroids, calcineurin inhibitors and NB-UVB phototherapy. Camouflage can also be prescribed to help mask the appearance of vitiligo, although this is frequently only prescribed for the face.

AB - Vitiligo is characterised by well demarcated, cutaneous, macular depigmentation, with worldwide prevalence estimated to be between 0.2-1.8% [1]. Vitiligo treatments aim to encourage re-pigmentation and include topical corticosteroids, calcineurin inhibitors and NB-UVB phototherapy. Camouflage can also be prescribed to help mask the appearance of vitiligo, although this is frequently only prescribed for the face.

U2 - 10.1111/bjd.15881

DO - 10.1111/bjd.15881

M3 - Article

VL - 178

SP - e57–e58

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 1

ER -